Clarivate Plc, a global leader in connecting people and organizations to intelligence they can trust to transform their world, has announced the launch of VeriSIM Life Translational Index™ on Cortellis Drug Discovery Intelligence by Clarivate. The integrated workflow provides customers with a diverse array of predictive compound safety and efficacy insights, including bioavailability, hepatic and renal clearance, clinical toxicity, first-in-human dose, and more.
The new solution serves as the next phase of an expanding partnership between Clarivate and VeriSIM Life, the leading artificial intelligence (AI)-enabled, R&D decisions de-risker for breakthrough drug development, announced earlier this year.
The FDA deems the cost and time associated with translating drug candidates to successful clinical trial outcomes to be “unsustainable” for the pharmaceutical industry. Accurate objective data and predictive analytics are needed to enable informed decision-making and pharma and biopharma organizations must optimize their tools to efficiently translate data into insights that can accelerate drug development.
This solution seamlessly integrates VeriSIM Life Translational Index™, an innovative approach to helping researchers make early and accurate predictions about compound safety and efficacy, with Cortellis Drug Discovery Intelligence by Clarivate, a leading source of pharma and drug research and development intelligence. Customers can access enhanced R&D insights to help better evaluate the therapeutic potential of key compounds. These insights serve as a material aid to fuel informed experimentation and decision-making, guiding critical aspects of drug development, including the route of administration, dosing, toxicity, human variability, and other key requirements in the drug development cycle.
Through the integration of the VeriSIM Life Translational Index and Cortellis Drug Discovery Intelligence, researchers can now access more comprehensive insights to help accelerate the preclinical translation phase of drug development by augmenting Cortellis Drug Discovery Intelligence and OFF-X data with comprehensive, AI-enabled insights on toxicology, species-specific drug exposure, and clinical translatability, even in the absence of published data, empowering them to make informed decisions with statistical power.
As a provider of best-in-class data integration/deidentified patient solutions and a premier end-to-end research intelligence solution, Clarivate is committed to comprehensively supporting customers across the entire drug, device, or diagnostic product lifecycle to help them advance human health. Clarivate will continue to invest in artificial intelligence (AI) and machine learning (ML) that support the industry’s ever-growing need to engage patients, physicians, and payers in new ways, navigate barriers to access and adherence, and address patient unmet needs.
Click here to read the original press release.
